Allergan Can’t Dodge Stock Drop Suit Over Breast Implants

Sept. 23, 2019, 6:37 PM

Allergan PLC failed to shake off a proposed securities fraud class action alleging the company concealed the dangers of its breast implant products.

The proposed class may proceed with claims that the company didn’t tell the whole truth about the link between a rare form of blood cancer and its silicone-gel breast implants, the U.S. District Court for the Southern District of New York said.

The complaint doesn’t show a definitive link between the implant products and anaplastic large cell lymphoma, the court said.

But allegations that the company’s disclosures gave investors a false impression that its implants were no ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.